بدائل البحث:
parent decrease » largest decrease (توسيع البحث), point decrease (توسيع البحث), largest decreases (توسيع البحث)
large decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث), large increases (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
_ parent » _ parents (توسيع البحث), _ parental (توسيع البحث), _ part (توسيع البحث)
parent decrease » largest decrease (توسيع البحث), point decrease (توسيع البحث), largest decreases (توسيع البحث)
large decrease » larger decrease (توسيع البحث), marked decrease (توسيع البحث), large increases (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
_ parent » _ parents (توسيع البحث), _ parental (توسيع البحث), _ part (توسيع البحث)
-
1
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
منشور في 2025"…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. …"
-
2
-
3
-
4
ECoG timescales decrease during spatial attention.
منشور في 2025"…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …"
-
5
-
6
-
7
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
منشور في 2024"…(<b>C</b>) Y-27632 collaborated with BA to alleviate the decrease in FD-4 flux in LPS-induced Caco2 cells on day 22. …"
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
منشور في 2025الموضوعات: -
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
منشور في 2025الموضوعات: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
منشور في 2025الموضوعات: -
18
-
19
Baseline patient characteristics across neutralizing monoclonal antibody trials.
منشور في 2025الموضوعات: -
20